Revised Draft Document “Asbestos Fibers and Other Elongated Mineral Particles: State of the Science and Roadmap for Research”, 43242-43243 [E8-16946]
Download as PDF
43242
Federal Register / Vol. 73, No. 143 / Thursday, July 24, 2008 / Notices
development, delivery and
communication of public health
services and information at CDC and to
address emerging programmatic needs.
Every National Center and Office at
CDC will have the opportunity to utilize
this generic clearance. There is no cost
to the respondents other than their time.
The total estimated burden hours are
38,700.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents
Number of
responses per
respondent
Average burden
per response
(in hours)
CDC Partners, Public Health Professionals, Health Care Professionals, General Public ..................................................................................................................................
86,000
1
27/60
Dated: July 16, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–16945 Filed 7–23–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH 099-A]
Revised Draft Document ‘‘Asbestos
Fibers and Other Elongated Mineral
Particles: State of the Science and
Roadmap for Research’’
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of Draft Document
Available for Public Comment.
ebenthall on PRODPC60 with NOTICES
AGENCY:
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the following revised draft
document available for public comment
entitled ‘‘Asbestos Fibers and Other
Elongated Mineral Particles: State of the
Science and Roadmap for Research.’’
The document and instructions for
submitting comments can be found at
https://www.cdc.gov/niosh/review/
public/099-A/.
Public Comment Period: July 24, 2008
through September 30, 2008.
Status: Written comments may be
mailed to the attention of Diane Miller,
NIOSH Docket Office, Robert A. Taft
Laboratories, 4676 Columbia Parkway,
MS-C34, Cincinnati, Ohio 45226,
telephone (513) 533–8450, facsimile
(513) 533–8285. Comments may also be
submitted by e-mail to
nioshdocket@cdc.gov. All material
submitted to the Agency should
reference the NIOSH Docket number
VerDate Aug<31>2005
15:14 Jul 23, 2008
Jkt 214001
099-A. All electronic comments should
be formatted as Microsoft Word.
All information received in response
to this notice will be available for public
examination and copying at the NIOSH
Docket Office, 4676 Columbia Parkway,
Cincinnati, Ohio 45226.
Purpose: To obtain comments from
the public on the revised draft
document entitled, ‘‘Asbestos Fibers
and Other Elongated Mineral Particles:
State of the Science and Roadmap for
Research,’’ referred to as Roadmap.
Asbestos has been a highly visible issue
in public health for over three decades.
Many advances have been made in the
scientific understanding of worker
health effects from exposure to asbestos
and other elongated mineral particles
(EMPs), and it is now well documented
that fibers of asbestos minerals, when
inhaled, can cause serious diseases in
exposed workers. Yet, many questions
and areas of scientific uncertainty
remain.
Background: As the Federal agency
responsible for conducting research and
making recommendations for the
prevention of worker injury and illness,
NIOSH is undertaking a reappraisal of
how to ensure appropriate protection of
workers from exposure to asbestos fibers
and other EMPs. NIOSH prepared a first
draft of the document ‘‘Asbestos and
Other Mineral Fibers: A Roadmap for
Scientific Research,’’ and invited
comments at a public meeting, from the
Internet, and from selected expert peer
reviewers on the occupational health
issues identified and the framework for
research. As a result of comments
received during the public and expert
peer review process, NIOSH has
substantially revised the earlier draft
and is now inviting comments on a
revised draft of the document with the
new title ‘‘Asbestos Fibers and Other
Elongated Mineral Particles: State of the
Science and Roadmap for Research.’’
The previous draft, public comments,
peer review comments, and the
responses to peer reviewers’ comments
on the previous draft can be found at
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
https://www.cdc.gov/niosh/docket/
NIOSHdocket0099.html.
The purpose of the revised draft
Roadmap is to outline major areas of
controversy and to recommend a
research agenda that can serve as a
guide for the development of specific
research programs within and across
disciplines. The intended goal is to
provide answers to current scientific
questions, reduce scientific
uncertainties, and provide a sound
scientific foundation for future policy
development so that optimal health
protection can be assured.
NIOSH is seeking comments on the
scope and information used to support
the development of a research
framework for asbestos fibers and other
EMPs. Of special interest are comments
on the following revisions to the draft
document:
1. A discussion of particle
characteristics (e.g., dimension,
chemistry) and their potential influence
on biological responses (Sections 1.6.1,
1.6.2, 1.6.3, and 1.6.4).
2. Toxicological research with EMPs
(Section 2.2).
3. Epidemiological studies of workers
exposed to EMPs (Section 2.3.3).
4. Capabilities and limitations of
analytical instruments used to identify
EMPs (Section 2.4.2).
Also of special interest are comments
on the entirely new content in the
document:
1. A rephrasing of the NIOSH
recommended exposure limit (REL) for
asbestos and related EMPs (Section
1.8.2).
2. The inclusion of ‘‘How the
proposed research could lead to the
development of improved public health
policies for asbestos and other EMPs’’
(Section 2.5).
3. Clinical issues (Section 1.4).
4. Recommendations for clinical
research (Section 2.3.4).
NIOSH continues to be interested in
available and forthcoming research
results that can help answer the
questions set forth in the Roadmap, as
well as information on existing
E:\FR\FM\24JYN1.SGM
24JYN1
Federal Register / Vol. 73, No. 143 / Thursday, July 24, 2008 / Notices
workplace exposure data, health effects,
and control technologies.
Submitted comments on the revised
draft Roadmap should indicate the
pertinent page(s) and line(s) in the draft
document being addressed.
Contact Person for Technical
Information: Paul Middendorf, Office of
the Director, NIOSH, CDC, telephone
(513) 533–8606, e-mail
pmiddendorf@cdc.gov.
Dated: July 16, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E8–16946 Filed 7–23–08; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Exclusive
License: Respiratory Syncytial Virus
Vaccine or Therapeutic
Technology Transfer Office,
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
and other materials relating to the
contemplated license should be directed
to Andrew Watkins, J.D., Ph.D.,
Director, Technology Transfer Office,
Centers for Disease Control and
Prevention (CDC), 4770 Buford
Highway, Mailstop K–79, Atlanta, GA
30341, telephone: (770) 488–8600;
facsimile: (770) 488–8615. Applications
for a license filed in response to this
notice will be treated as objections to
the grant of the contemplated license.
Only written comments and/or
applications for a license which are
received by CDC within thirty days of
this notice will be considered.
Comments and objections submitted in
response to this notice will not be made
available for public inspection, and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 17, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E8–16943 Filed 7–23–08; 8:45 am]
BILLING CODE 4163–18–P
ebenthall on PRODPC60 with NOTICES
AGENCY:
SUMMARY: This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Centers for Disease
Control and Prevention (CDC),
Technology Transfer Office, Department
of Health and Human Services (DHHS),
is contemplating the grant of a
worldwide exclusive license to practice
the inventions embodied in the patent
referred to below to Trellis Bioscience,
Inc., having a place of business in South
San Francisco, CA. The patent rights in
these inventions have been assigned to
the government of the United States of
America. The patent(s) to be licensed
are: U.S. Patent Application 11/139,372
entitled ‘‘Compositions and Methods for
Modulating RSV Infection and
Immunity,’’ priority date 10.18.2000,
and all related foreign patent
applications. CDC Technology ID No. I–
022–00.
Status: Published.
Priority Date: 10.18.2000
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
Technology: This technology provides
new methods for prevention and
treatment of respiratory syncytial virus
(RSV) infection.
ADDRESSES: Requests for a copy of this
patent application, inquiries, comments,
VerDate Aug<31>2005
15:14 Jul 23, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
43243
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7188,
Bethesda, MD 20892–7924, 301–435–0280,
krullh@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 17, 2008.
David Clary,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–16841 Filed 7–23–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[FEMA–2005–0005]
Z–RIN 1660–ZA01
Disaster Assistance Directorate Policy
Numbers 9100.1 and 9523.1 Snow
Assistance and Severe Winter Storm
Policy
Federal Emergency
Management Agency, DHS.
ACTION: Notice of proposed policy and
opportunity for comment.
AGENCY:
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Research Demonstration and Dissemination
Projects.
Date: August 19, 2008.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge Two, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Holly K. Krull, PhD,
Scientific Review Officer, Review Branch/
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
SUMMARY: The Federal Emergency
Management Agency (FEMA) proposes
to revise its Snow Assistance and Severe
Winter Storm Policy. The current policy
provides the procedures and
requirements for FEMA in making
recommendations to the President for
either a declaration of emergency or a
major disaster resulting from a
snowstorm. This proposed policy would
maintain the current policy requirement
that a county experience a ‘‘record or
near-record’’ snowfall, but also would
require that the State meet the
requirements of a major disaster
declaration. It would stipulate that the
Governor must direct execution of the
State emergency plan and the State must
demonstrate that the capabilities of the
State to effectively respond to the event
are or will be exceeded. States and
communities requesting aid also would
be required to submit an estimate of
eligible public assistance costs (estimate
of public assistance divided by county
and State populations, respectively),
including snow assistance costs for a 48hour period that meet or exceed the
county and statewide per capita cost
threshold. These proposed criteria are
used by FEMA solely for consideration
E:\FR\FM\24JYN1.SGM
24JYN1
Agencies
[Federal Register Volume 73, Number 143 (Thursday, July 24, 2008)]
[Notices]
[Pages 43242-43243]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-16946]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH 099-A]
Revised Draft Document ``Asbestos Fibers and Other Elongated
Mineral Particles: State of the Science and Roadmap for Research''
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of Draft Document Available for Public Comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
announces the following revised draft document available for public
comment entitled ``Asbestos Fibers and Other Elongated Mineral
Particles: State of the Science and Roadmap for Research.'' The
document and instructions for submitting comments can be found at
https://www.cdc.gov/niosh/review/public/099-A/.
Public Comment Period: July 24, 2008 through September 30, 2008.
Status: Written comments may be mailed to the attention of Diane
Miller, NIOSH Docket Office, Robert A. Taft Laboratories, 4676 Columbia
Parkway, MS-C34, Cincinnati, Ohio 45226, telephone (513) 533-8450,
facsimile (513) 533-8285. Comments may also be submitted by e-mail to
nioshdocket@cdc.gov. All material submitted to the Agency should
reference the NIOSH Docket number 099-A. All electronic comments should
be formatted as Microsoft Word.
All information received in response to this notice will be
available for public examination and copying at the NIOSH Docket
Office, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
Purpose: To obtain comments from the public on the revised draft
document entitled, ``Asbestos Fibers and Other Elongated Mineral
Particles: State of the Science and Roadmap for Research,'' referred to
as Roadmap. Asbestos has been a highly visible issue in public health
for over three decades. Many advances have been made in the scientific
understanding of worker health effects from exposure to asbestos and
other elongated mineral particles (EMPs), and it is now well documented
that fibers of asbestos minerals, when inhaled, can cause serious
diseases in exposed workers. Yet, many questions and areas of
scientific uncertainty remain.
Background: As the Federal agency responsible for conducting
research and making recommendations for the prevention of worker injury
and illness, NIOSH is undertaking a reappraisal of how to ensure
appropriate protection of workers from exposure to asbestos fibers and
other EMPs. NIOSH prepared a first draft of the document ``Asbestos and
Other Mineral Fibers: A Roadmap for Scientific Research,'' and invited
comments at a public meeting, from the Internet, and from selected
expert peer reviewers on the occupational health issues identified and
the framework for research. As a result of comments received during the
public and expert peer review process, NIOSH has substantially revised
the earlier draft and is now inviting comments on a revised draft of
the document with the new title ``Asbestos Fibers and Other Elongated
Mineral Particles: State of the Science and Roadmap for Research.'' The
previous draft, public comments, peer review comments, and the
responses to peer reviewers' comments on the previous draft can be
found at https://www.cdc.gov/niosh/docket/NIOSHdocket0099.html.
The purpose of the revised draft Roadmap is to outline major areas
of controversy and to recommend a research agenda that can serve as a
guide for the development of specific research programs within and
across disciplines. The intended goal is to provide answers to current
scientific questions, reduce scientific uncertainties, and provide a
sound scientific foundation for future policy development so that
optimal health protection can be assured.
NIOSH is seeking comments on the scope and information used to
support the development of a research framework for asbestos fibers and
other EMPs. Of special interest are comments on the following revisions
to the draft document:
1. A discussion of particle characteristics (e.g., dimension,
chemistry) and their potential influence on biological responses
(Sections 1.6.1, 1.6.2, 1.6.3, and 1.6.4).
2. Toxicological research with EMPs (Section 2.2).
3. Epidemiological studies of workers exposed to EMPs (Section
2.3.3).
4. Capabilities and limitations of analytical instruments used to
identify EMPs (Section 2.4.2).
Also of special interest are comments on the entirely new content
in the document:
1. A rephrasing of the NIOSH recommended exposure limit (REL) for
asbestos and related EMPs (Section 1.8.2).
2. The inclusion of ``How the proposed research could lead to the
development of improved public health policies for asbestos and other
EMPs'' (Section 2.5).
3. Clinical issues (Section 1.4).
4. Recommendations for clinical research (Section 2.3.4).
NIOSH continues to be interested in available and forthcoming
research results that can help answer the questions set forth in the
Roadmap, as well as information on existing
[[Page 43243]]
workplace exposure data, health effects, and control technologies.
Submitted comments on the revised draft Roadmap should indicate the
pertinent page(s) and line(s) in the draft document being addressed.
Contact Person for Technical Information: Paul Middendorf, Office
of the Director, NIOSH, CDC, telephone (513) 533-8606, e-mail
pmiddendorf@cdc.gov.
Dated: July 16, 2008.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E8-16946 Filed 7-23-08; 8:45 am]
BILLING CODE 4163-19-P